M Charlton

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database
    Michael Charlton
    Liver Transpl 10:1120-30. 2004
  2. ncbi request reprint Recurrence of hepatitis C infection: Where are we now?
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl . 2005
  3. ncbi request reprint Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis?
    Michael Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Nat Clin Pract Gastroenterol Hepatol 3:72-3. 2006
  4. doi request reprint A practical guide to the management of HCV infection following liver transplantation
    K Watt
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 9:1707-13. 2009
  5. doi request reprint Evolving aspects of liver transplantation for nonalcoholic steatohepatitis
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Curr Opin Organ Transplant 18:251-8. 2013
  6. pmc Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition
    Michael Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 301:G825-34. 2011
  7. ncbi request reprint Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence
    Michael Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 9:S58-62. 2003
  8. ncbi request reprint Management of recurrence of hepatitis C infection following liver transplantation
    M Charlton
    Transplant Center, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Minerva Chir 58:717-24. 2003
  9. ncbi request reprint Natural history and management of hepatitis C infection after liver transplantation
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Semin Liver Dis 24:79-88. 2004
  10. ncbi request reprint Branched-chain amino acid enriched supplements as therapy for liver disease
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Nutr 136:295S-8S. 2006

Research Grants

  1. Pathophysiology and Characterisation of NAFLD
    Michael Charlton; Fiscal Year: 2007
  2. Pathophysiology and Characterisation of NAFLD
    Michael Charlton; Fiscal Year: 2009

Collaborators

Detail Information

Publications42

  1. ncbi request reprint Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database
    Michael Charlton
    Liver Transpl 10:1120-30. 2004
    ..Long-term death and graft loss specifically secondary to recurrence of HCV appears, however, to be determined primarily by factors other than those included in this analysis...
  2. ncbi request reprint Recurrence of hepatitis C infection: Where are we now?
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl . 2005
    ..3. Treatment of recipients with histological recurrence is with pegylated IFN (+/- ribavirin). The role of hepatitis C immunoglobulin in the management of postransplant HCV is still evolving. (..
  3. ncbi request reprint Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis?
    Michael Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Nat Clin Pract Gastroenterol Hepatol 3:72-3. 2006
  4. doi request reprint A practical guide to the management of HCV infection following liver transplantation
    K Watt
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    Am J Transplant 9:1707-13. 2009
    ..Because of the high frequency of hemotoxicity and renal insufficiency, ribavirin should be dosed according to renal function...
  5. doi request reprint Evolving aspects of liver transplantation for nonalcoholic steatohepatitis
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Curr Opin Organ Transplant 18:251-8. 2013
    ..NASH, a rare indication for liver transplantation in the early 1990s, is now the third most common indication. This review considers key aspects of the liver transplantation for NASH...
  6. pmc Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition
    Michael Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 301:G825-34. 2011
    ..This represents a novel small animal model of fibrosing NASH with high fidelity to the human condition. These results highlight the contribution of dietary composition to the development of nonalcoholic fatty liver disease and NASH...
  7. ncbi request reprint Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence
    Michael Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 9:S58-62. 2003
    ..8. A correlation between early levels of viremia and subsequent allograft injury suggests that initiation of antiviral therapy early in the posttransplant course might be desirable...
  8. ncbi request reprint Management of recurrence of hepatitis C infection following liver transplantation
    M Charlton
    Transplant Center, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Minerva Chir 58:717-24. 2003
    ..Passive immunity, through anti-HCV antibody preparations, has not been efficacious to date. The role of hepatitis C new immunosuppression agents in the management of posttransplant hepatitis C infection is still evolving...
  9. ncbi request reprint Natural history and management of hepatitis C infection after liver transplantation
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Semin Liver Dis 24:79-88. 2004
    ..This article describes the natural history, risk factors, and current strategies for the amelioration of posttransplant HCV infection...
  10. ncbi request reprint Branched-chain amino acid enriched supplements as therapy for liver disease
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Nutr 136:295S-8S. 2006
    ..Cost and palatability may limit the potential applicability of this treatment modality...
  11. ncbi request reprint Impact of obesity on treatment of chronic hepatitis C
    Michael R Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:1177-86. 2006
    ....
  12. ncbi request reprint Approach to recurrent hepatitis C following liver transplantation
    Michael Charlton
    Transplant Center CH 10, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 9:23-30. 2007
    ..The role of hepatitis C immunoglobulin and new immunosuppressive agents in the management of hepatitis C after transplant continues to evolve...
  13. doi request reprint Obesity, hyperlipidemia, and metabolic syndrome
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 15:S83-9. 2009
    ..Treatment should be directed at managing obesity and complications of metabolic syndrome. Optimal immunosuppression in patients with nonalcoholic steatohepatitis is still evolving but should include steroid minimization...
  14. doi request reprint Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection
    Michael R Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 53:317-24. 2011
    ..0095). IL28B genotype was not significantly associated with survival (overall/liver-related)...
  15. doi request reprint Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States
    Michael R Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 141:1249-53. 2011
    ..The relative frequency of nonalcoholic steatohepatitis (NASH) as an indication for liver transplantation and comparative outcomes following transplantation are poorly understood...
  16. ncbi request reprint Natural history of hepatitis C and outcomes following liver transplantation
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Transplant Center CH 10, 200 First St S W, Rochester, MN 55905, USA
    Clin Liver Dis 7:585-602. 2003
    ..The role of hepatitis C immunoglobulin and new immunosuppression agents in the management of posttransplant hepatitis C infection is still evolving...
  17. ncbi request reprint Apolipoprotein synthesis in nonalcoholic steatohepatitis
    Michael Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 35:898-904. 2002
    ..In conclusion, because apoB-100 synthesis is a rate-determining step in hepatocyte lipid export, decreased synthesis of this protein may be an important factor in the development of hepatic steatosis, a prerequisite for NASH...
  18. ncbi request reprint The effect of insulin on human small intestinal mucosal protein synthesis
    M Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 118:299-306. 2000
    ..Because insulin is a postprandial hormone, it was hypothesized that it has an important role in regulating small intestinal protein synthesis in humans...
  19. ncbi request reprint Pre-emptive treatment of recurrent hepatitis C infection
    Michael Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 8:S50-4. 2002
  20. ncbi request reprint Hepatitis C infection in liver transplantation
    M Charlton
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Am J Transplant 1:197-203. 2001
    ..Overall, HCV-infected recipients who undergo retransplantation experience 5-year patient and graft survival rates that are similar to recipients undergoing retransplantation who are not HCV-infected...
  21. ncbi request reprint Insulin's effect on synthesis rates of liver proteins. A swine model comparing various precursors of protein synthesis
    B Ahlman
    Endocrine Research Unit, Division of Endocrinology and Metabolism, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Diabetes 50:947-54. 2001
    ..In contrast, insulin administration along with amino supplement is necessary to maintain albumin synthesis rate...
  22. ncbi request reprint Tissue-specific regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin
    Y Boirie
    Division of Endocrinology and Metabolism, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Diabetes 50:2652-8. 2001
    ..These results demonstrate that insulin has different effects on synthesis rates of specific protein fractions in the liver, heart, and skeletal muscle...
  23. ncbi request reprint Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease
    M Charlton
    Liver Transplant Unit, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 7:608-14. 2001
    ..9% of patients evaluated for liver transplantation at our center. Recurrence of steatosis and NASH is frequent and can be severe after liver transplantation...
  24. doi request reprint The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database
    J Leonard
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Am J Transplant 8:667-72. 2008
    ..Obesity, within the ranges observed in this study, should not be considered to be a contraindication to liver transplantation in the absence of other relative contraindications...
  25. doi request reprint Metabolic syndrome and liver transplantation: a review and guide to management
    Kymberly D S Watt
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, MN, USA
    J Hepatol 53:199-206. 2010
    ..Further study into the prevention and management of these issues in the transplant patient are needed...
  26. pmc The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population
    Apinya Leerapun
    Miles and Shirley Fiterman Center for Digestive Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 5:394-402; quiz 267. 2007
    ..We evaluated the utility of AFP-L3% for diagnosis of HCC in a US referral population...
  27. doi request reprint Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C
    Stanley S Liu
    Viral Hepatitis Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Gastroenterol 44:e178-85. 2010
    ..The aim of our study was to examine the influence of antidepressant treatment and whether this improves the likelihood of completing therapy...
  28. pmc Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis
    Yuko Akazawa
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Hepatol 52:586-93. 2010
    ..The mono-unsaturated free fatty acid palmitoleate is an adipose-derived lipokine which suppresses free fatty acid-mediated lipotoxicity by unclear mechanisms. Herein we examined the mechanisms responsible for cytoprotection...
  29. ncbi request reprint Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C
    Kelly W Burak
    Transplant Center, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 8:362-9. 2002
    ..Whether CMV mediates this by inducing increased immunosuppression or directly enhancing HCV replication requires further study...
  30. pmc Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis
    Robert C Huebert
    Gastroenterology Research Unit, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 52:238-48. 2010
    ..Additionally, AQP-1 localizes to plasma membrane blebs, where it increases osmotic water permeability and locally facilitates the rapid, trans-membrane flux of water...
  31. pmc JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis
    Sophie C Cazanave
    Miles and Shirley Fitterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 284:26591-602. 2009
    ..Collectively, the data implicate JNK1-dependent PUMA expression as a mechanism contributing to hepatocyte lipoapoptosis...
  32. ncbi request reprint Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation
    Raghavakaimal Sreekumar
    Transplant Center, Mayo Clinic and Foundation, Rochester, MN, USA
    Liver Transpl 8:814-21. 2002
    ..Further studies are required to determine whether gene expression profiles, either intragraft or in serum, can be used for the diagnosis and differentiation of ACR from recurrence of HCV...
  33. ncbi request reprint Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis
    Juan F Gallegos-Orozco
    Division of Transplantation Medicine, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Am J Gastroenterol 100:874-8. 2005
    ..We sought to determine if PSC patients have a higher frequency of common CF alleles than disease controls...
  34. ncbi request reprint A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation
    Jeffrey S Crippin
    Baylor University Medical Center, Dallas, TX, USA
    Liver Transpl 8:350-5. 2002
    ....
  35. ncbi request reprint Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation
    Samer Gawrieh
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 11:1207-13. 2005
    ..In conclusion, early activation of mesenchymal HSCs is a marker for progressive fibrosis in patients with hepatitis C post-LT and may help select patients who would benefit from HCV or HSC-targeted therapy...
  36. ncbi request reprint Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire?
    Michael R Charlton
    Liver Transpl 8:47-9. 2002
  37. ncbi request reprint Origin of adenocarcinoma in a transplanted liver determined by microsatellite analysis
    Sanjay Kakar
    Division of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Hum Pathol 33:435-6. 2002
    ..The allelic patterns of tumor DNA were identical to those of donor DNA and were distinct from the DNA profile of the recipient. The use of MS analysis clearly established that the adenocarcinoma was of donor origin...
  38. ncbi request reprint Hypophosphatemia after right hepatectomy for living donor liver transplantation
    Kelly W Burak
    Transplant Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Can J Gastroenterol 18:729-33. 2004
    ..All living donors should be monitored for the development of hypophosphatemia during the first two postoperative weeks...
  39. ncbi request reprint Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant
    Timothy J Gunneson
    Transplant Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:1472-5. 2002
    ..We report on the complication rate and efficiency of ultrasound-assisted percutaneous liver biopsy performed by an experienced physician assistant...
  40. ncbi request reprint The pathogenesis of hepatitis C virus is influenced by cytomegalovirus
    Raymund R Razonable
    Division of Infectious Diseases and Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Clin Infect Dis 35:974-81. 2002
    ..05) and had a trend toward a higher hepatitis activity index (P=.10) and HCV load (P=.10) at 16 weeks after liver transplantation. The pathogenesis of HCV is influenced by its interaction with CMV but not with HHV-6...
  41. ncbi request reprint Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant
    Jeffrey J Germer
    Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA
    Am J Transplant 3:743-53. 2003
    ..Determination of HBV genotype, as well as identification of HBV polymerase and S gene mutations in liver transplant candidates may be warranted to optimize HBV management strategies post transplant...
  42. ncbi request reprint Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation
    Maureen M J Guichelaar
    Division of Liver Transplantation, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Am J Transplant 3:885-90. 2003
    ..A pretransplant diagnosis of autoimmune hepatitis has been identified as a novel independent risk factor for NAS formation. Development of NAS significantly attenuates graft but not patient survival...

Research Grants4

  1. Pathophysiology and Characterisation of NAFLD
    Michael Charlton; Fiscal Year: 2007
    ..We believe that these experiments will generate mechanistic insight into the cause and effects of increased oxidative stress in patients with histologically progressive NAFLD. ..
  2. Pathophysiology and Characterisation of NAFLD
    Michael Charlton; Fiscal Year: 2009
    ..We believe that these experiments will generate mechanistic insight into the cause and effects of increased oxidative stress in patients with histologically progressive NAFLD. ..